Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
| Regarding changes in the Management Board of JSC “Grindeks” subsidiary JSC “Kalceks” | ||
| By: GlobeNewswire - 19 Feb 2020 | Back to overview list |
|
As of February 18, the Management Board of JSC “Kalceks”, a subsidiary of “Grindeks”, has been changed – the member of the Management Board Egils Kopstals has been appointed as the new Chairman of the Board of JSC “Kalceks”. Kaspars Kuprevics, the Quality and R&D Director/Qualified person has also joined JSC “Kalceks” Management Board. Juris Hmelnickis, who was the Chairman of the Board of JSC “Kalceks” since 2014 and who on 4 February 2020 was approved by the Supervisory Council of JSC “Grindeks” as the new Chairman of the Board of JSC “Grindeks”, will continue to actively participate in JSC “Kalceks”, performing the duties of a member of the Management Board. Egils Kopstals has 20 years of experience in JSC “Grindeks” group as he joined JSC “Kalceks” in 2000. Simultaneously with working at JSC “Kalceks” has was also the Head of Investment Department of JSC “Grindeks” from 2007 to 2012 and the Chief Economist from 2012. Since 2018 Egils Kopstals has been working at JSC “Kalceks” only. Kaspars Kuprevics is the Quality and R&D Director and has been working in the pharmaceutical and chemistry industry since 2006. Kaspars Kuprevics joined JSC “Kalceks” in 2015 as a qualified person. He begun working in JSC “Grindeks” in 2006 as technician in Chromatography Laboratory but gradually extended his career and became the Head of the Quality Control Laboratory. About JSC “Grindeks” “Grindeks” is an international pharmaceutical company focused on research, development, manufacturing and sales of original products, generics and active pharmaceutical ingredients. The Group of “Grindeks” has four subsidiary companies in Latvia, Estonia, and Slovakia as well as representative offices in 11 countries. “Grindeks” specializes in the heart and cardiovascular, CNS, anti-cancer and gastroenterological medication therapeutic groups. A range of products covers a combination of original products Mildronate® (meldonium*) and Ftorafur®, generics, food supplements and active pharmaceutical ingredients. *Notice: meldonium is included in the list of substances prohibited in sport. Further information: Olga Grisina
|
||
|
|
||
 | Back to overview list | |